Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Am Fam Physician ; 101(8): 472-480, 2020 04 15.
Article in English | MEDLINE | ID: mdl-32293842

ABSTRACT

Chronic diarrhea is defined as a predominantly loose stool lasting longer than four weeks. A patient history and physical examination with a complete blood count, C-reactive protein, anti-tissue transglutaminase immunoglobulin A (IgA), total IgA, and a basic metabolic panel are useful to evaluate for pathologies such as celiac disease or inflammatory bowel disease. More targeted testing should be based on the differential diagnosis. When the differential diagnosis is broad, stool studies should be used to categorize diarrhea as watery, fatty, or inflammatory. Some disorders can cause more than one type of diarrhea. Watery diarrhea includes secretory, osmotic, and functional types. Functional disorders such as irritable bowel syndrome and functional diarrhea are common causes of chronic diarrhea. Secretory diarrhea can be caused by bile acid malabsorption, microscopic colitis, endocrine disorders, and some postsurgical states. Osmotic diarrhea can present with carbohydrate malabsorption syndromes and laxative abuse. Fatty diarrhea can be caused by malabsorption or maldigestion and includes disorders such as celiac disease, giardiasis, and pancreatic exocrine insufficiency. Inflammatory diarrhea warrants further evaluation and can be caused by disorders such as inflammatory bowel disease, Clostridioides difficile, colitis, and colorectal cancer.


Subject(s)
Celiac Disease , Inflammatory Bowel Diseases , Malabsorption Syndromes , Adult , Celiac Disease/complications , Celiac Disease/diagnosis , Chronic Disease , Diagnosis, Differential , Diarrhea/diagnosis , Diarrhea/etiology , Humans , Immunoglobulin A , Malabsorption Syndromes/complications , Malabsorption Syndromes/diagnosis
2.
Am Fam Physician ; 97(5): 331-336, 2018 Mar 01.
Article in English | MEDLINE | ID: mdl-29671505

ABSTRACT

Colorectal cancer is the fourth most common cancer in the United States and has a five-year survival rate of 65%. The American Cancer Society and other experts have released guidelines on surveillance, health promotion, screening for other malignancies, and management of treatment effects. Surveillance for disease recurrence should occur every three to six months for the first two to three years, then every six months for a total of five years. Each visit should include a history and physical examination, routine care for chronic medical conditions, and screening for other primary cancers according to guidelines for the general population. Topics addressed depend on the treatment utilized but generally include gastrointestinal issues, neuropathy, pain, urinary symptoms, fatigue, psychological issues, cognitive problems, sexual symptoms, and stoma care. Carcinoembryonic antigen testing should be performed at each visit in patients who are candidates for further intervention. Chest, abdomen, and pelvic computed tomography should be performed annually for five years after treatment. Colonoscopy should be repeated one year after treatment, then three years later if no advanced adenoma is identified.


Subject(s)
American Cancer Society , Cancer Survivors , Colorectal Neoplasms/therapy , Disease Management , Population Surveillance , Survivors/statistics & numerical data , Colorectal Neoplasms/epidemiology , Humans , Prevalence , Survival Rate/trends , United States/epidemiology
3.
Am Fam Physician ; 95(1): 22-28, 2017 Jan 01.
Article in English | MEDLINE | ID: mdl-28075104

ABSTRACT

Esophageal cancer has a poor prognosis and high mortality rate, with an estimated 16,910 new cases and 15,910 deaths projected in 2016 in the United States. Squamous cell carcinoma and adenocarcinoma account for more than 95% of esophageal cancers. Squamous cell carcinoma is more common in nonindustrialized countries, and important risk factors include smoking, alcohol use, and achalasia. Adenocarcinoma is the predominant esophageal cancer in developed nations, and important risk factors include chronic gastroesophageal reflux disease, obesity, and smoking. Dysphagia alone or with unintentional weight loss is the most common presenting symptom, although esophageal cancer is often asymptomatic in early stages. Physicians should have a low threshold for evaluation with endoscopy if any symptoms are present. If cancer is confirmed, integrated positron emission tomography and computed tomography should be used for initial staging. If no distant metastases are found, endoscopic ultrasonography should be performed to determine tumor depth and evaluate for nodal involvement. Localized tumors can be treated with endoscopic mucosal resection, whereas regional tumors are treated with esophagectomy, neoadjuvant chemotherapy, chemoradiotherapy, or a combination of modalities. Nonresectable tumors or tumors with distant metastases are treated with palliative interventions. Specific prevention strategies have not been proven, and there are no recommendations for esophageal cancer screening.


Subject(s)
Esophageal Neoplasms/diagnosis , Esophageal Neoplasms/therapy , Age Factors , Aged , Aged, 80 and over , Alcohol Drinking/adverse effects , Chemotherapy, Adjuvant , Combined Modality Therapy , Controlled Clinical Trials as Topic , Decision Support Techniques , Esophageal Neoplasms/diagnostic imaging , Esophageal Neoplasms/pathology , Esophagus/diagnostic imaging , Female , Humans , Male , Middle Aged , Neoadjuvant Therapy , Neoplasm Staging , Radiotherapy, Adjuvant , Sex Factors , Smoking/adverse effects , Tomography, X-Ray Computed , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...